Simplify myeloid malignancy profiling with NGS One comprehensive assay for all relevant DNA mutations and fusion transcripts.

Myeloid malignancies are complex and highly heterogeneous diseases with many subtypes and oncogenic drivers in play. Sequential approaches for analyzing myeloid malignancies can be laborious and time consuming. As the number of relevant biomarkers continues to grow, a more streamlined approach is needed to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers. Next-generation sequencing (NGS) with the Oncomine Myeloid Research Assay is an optimal solution, enabling comprehensive assessment of all relevant molecular markers in a single test.
 

Hear what our customers have to say about the Oncomine Myeloid Research Assay